Literature DB >> 17294149

[Treatment of borderline personality disorder with atypical antipsychotic drugs].

A Mobascher1, J Mobascher, C Schmahl, J Malevani.   

Abstract

Pharmacotherapy of Borderline personality disorder with atypical antipsychotics has recently been the subject of several mostly small studies and case reports. In contrast to the frequent clinical use of this substance class in borderline patients the amount of data on that subject is still sparse. The clinical data gathered thus far suggest a potential use of atypical antipsychotics in the areas of psychotic symptoms, impulsivity and possibly affective symptoms. The drugs were sufficiently well tolerated; however, the observation period in most studies was short and the dosage low. The current set of clinical data does not support the frequently applied polypharmacy. However, recent data suggest that a therapeutic approach combining atypical antipsychotics and psychotherapy may reveal synergistic effects. Future trials should study larger sample sizes over a longer period of time. Open questions are the required dose and the optimal treatment duration.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17294149     DOI: 10.1007/s00115-006-2243-3

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  28 in total

1.  Combined dialectical behavior therapy and fluoxetine in the treatment of borderline personality disorder.

Authors:  Elizabeth B Simpson; Shirley Yen; Ellen Costello; Karen Rosen; Ann Begin; Jacqueline Pistorello; Teri Pearlstein
Journal:  J Clin Psychiatry       Date:  2004-03       Impact factor: 4.384

2.  Aripiprazole pharmacotherapy of borderline personality disorder.

Authors:  A Mobascher; J Mobascher; V Schlemper; G Winterer; J Malevani
Journal:  Pharmacopsychiatry       Date:  2006-05       Impact factor: 5.788

3.  Two-year randomized controlled trial and follow-up of dialectical behavior therapy vs therapy by experts for suicidal behaviors and borderline personality disorder.

Authors:  Marsha M Linehan; Katherine Anne Comtois; Angela M Murray; Milton Z Brown; Robert J Gallop; Heidi L Heard; Kathryn E Korslund; Darren A Tutek; Sarah K Reynolds; Noam Lindenboim
Journal:  Arch Gen Psychiatry       Date:  2006-07

4.  Olanzapine safety and efficacy in patients with borderline personality disorder and comorbid dysthymia.

Authors:  S C Schulz; K L Camlin; S A Berry; J A Jesberger
Journal:  Biol Psychiatry       Date:  1999-11-15       Impact factor: 13.382

5.  Efficacy and tolerability of quetiapine in the treatment of borderline personality disorder: A pilot study.

Authors:  Silvio Bellino; Erika Paradiso; Filippo Bogetto
Journal:  J Clin Psychiatry       Date:  2006-07       Impact factor: 4.384

6.  SSRI treatment of borderline personality disorder: a randomized, placebo-controlled clinical trial for female patients with borderline personality disorder.

Authors:  Thomas Rinne; Wim van den Brink; Luuk Wouters; Richard van Dyck
Journal:  Am J Psychiatry       Date:  2002-12       Impact factor: 18.112

7.  Quetiapine in the treatment of borderline personality disorder.

Authors:  Eva Hilger; Christian Barnas; Siegfried Kasper
Journal:  World J Biol Psychiatry       Date:  2003-01       Impact factor: 4.132

8.  Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD): a continuous measure of DSM-IV borderline psychopathology.

Authors:  Mary C Zanarini; Anna A Vujanovic; Elizabeth A Parachini; Jennifer L Boulanger; Frances R Frankenburg; John Hennen
Journal:  J Pers Disord       Date:  2003-06

9.  A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder.

Authors:  Mary C Zanarini; Frances R Frankenburg; Elizabeth A Parachini
Journal:  J Clin Psychiatry       Date:  2004-07       Impact factor: 4.384

10.  The longitudinal course of borderline psychopathology: 6-year prospective follow-up of the phenomenology of borderline personality disorder.

Authors:  Mary C Zanarini; Frances R Frankenburg; John Hennen; Kenneth R Silk
Journal:  Am J Psychiatry       Date:  2003-02       Impact factor: 18.112

View more
  1 in total

Review 1.  Borderline personality disorder and psychosis: a review.

Authors:  Sven Barnow; Elisabeth A Arens; Simkje Sieswerda; Ramona Dinu-Biringer; Carsten Spitzer; Simone Lang
Journal:  Curr Psychiatry Rep       Date:  2010-06       Impact factor: 5.285

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.